Compliance gaps not escalated during corporate review – CAPA program design
The initial signal that compliance gaps exist may arise from various facets of operations, including:Click to read the full article.
FUNCTIONAL AREAS
Third-party oversight failure before regulatory inspection – enforcement risk and mitigation plan
Mitigating Third-Party Oversight Failures Before Regulatory Inspections The risk posed by third-party oversight failures can severely jeopardize a pharmaceutical operation’s compliance status, particularly in advance of regulatory inspections. Such failures…
Compliance gaps not escalated during remediation – evidence pack for inspectors
The initial detection of compliance gaps typically arises from various sources, including deviations, out-of-specification (OOS) results, or even complaints from internal audits. Symptoms indicating such gaps often include:Click to read…
Internal audit findings ignored during remediation – how to satisfy FDA/EMA expectations
When internal audit findings are ignored, symptoms may manifest both in the manufacturing environment and within laboratory settings. Recognizing these signals early is critical to preventing larger compliance issues. Common…
Management review ineffective during corporate review – enforcement risk and mitigation plan
Identifying weak signals during manufacturing or quality control processes is crucial to prevent larger issues from emerging. Common symptoms of ineffective management reviews include:Click to read the full article.
Third-party oversight failure before regulatory inspection – evidence pack for inspectors
Identifying signals or symptoms of third-party oversight failures is crucial for timely interventions. Common indicators include:Click to read the full article.
Global SOP harmonization gaps during mock audit – evidence pack for inspectors
Identifying symptoms of SOP harmonization gaps is critical during a mock audit. Common indicators include:Click to read the full article.
Compliance gaps not escalated during enforcement response – enforcement risk and mitigation plan
Identifying compliance gaps before they escalate is crucial to maintaining a solid audit trail and ensuring GMP compliance. Various symptoms can alert operations teams to these inspection readiness concerns:Click to…
Global SOP harmonization gaps before regulatory inspection – preventing repeat observations
Identifying the manifestation of SOP harmonization gaps is the first step in addressing compliance issues. Here are typical signals to monitor in both manufacturing and laboratory settings:Click to read the…
Third-party oversight failure during remediation – CAPA program design
The first step in addressing third-party oversight failures is to identify the symptoms or signals that suggest an oversight issue. Common indicators include:Click to read the full article.
Inspection readiness untested during remediation – preventing repeat observations
The first sign of underlying issues often appears as deviations in the manufacturing process or results of laboratory tests. Symptoms can manifest in several concrete indicators, such as:Click to read…
Compliance gaps not escalated before regulatory inspection – how to satisfy FDA/EMA expectations
Symptoms and signals indicating compliance gaps can manifest in various ways within pharmaceutical operations. Awareness of these signs is the first step in an effective investigation. Below are common symptoms…